Plasminogen activation and cancer

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Extracellular matrix (ECM) degradation is essential for cancer cell invasion and metastasis.
• This breakdown is mediated by proteases, including serine proteases like plasmin and matrix metalloproteinases (MMPs).
• Protease activity is tightly regulated by activators, inhibitors, and cell surface receptors, forming a complex network.

Purpose of the Study:

• To explore the role of extracellular proteolysis in cancer invasion and metastasis.
• To investigate the potential of targeting proteases as a cancer therapy strategy.
• To address the challenges of protease inhibitor efficacy and toxicity in cancer treatment.

Main Methods:

• Analysis of the molecular components involved in extracellular proteolysis during cancer invasion.
• Examination of the interplay between cancer cells and stromal cells in regulating protease expression.
• Conceptualizing cancer invasion as a form of uncontrolled tissue remodeling.

Main Results:

• The generation of plasmin involves a cascade including plasminogen, urokinase-type plasminogen activator (uPA), its inhibitor PAI-1, the uPA receptor (uPAR), and alpha(2)-antiplasmin.
• Cancer invasion involves complex crosstalk between cancer and stromal cells, mirroring non-neoplastic tissue remodeling.
• Protease inhibition is a promising therapeutic avenue, but functional overlap among proteases necessitates combination therapies.

Conclusions:

• Cancer invasion can be viewed as dysregulated tissue remodeling driven by extracellular proteolysis.
• Direct inhibition of proteases presents therapeutic potential but faces challenges due to their diverse physiological roles.
• Optimizing combination protease inhibitor therapies is crucial for maximizing anti-cancer effects while minimizing systemic toxicity.